Investor Overview

Corporate Profile

We develop novel products based on our proprietary technologies for precision metering of gas flow. Our first commercial product, the CoSense® ETCO Monitor, measures end-tidal carbon dioxide (ETCO) in exhaled breath. The CoSense Monitor aids in the detection hemolysis, which is the breakdown of red blood cells. When present in babies with jaundice, hemolysis is a dangerous condition that can lead to long-term developmental disabilities. The CoSense Monitor also aids in the detection of smoke inhalation and carbon monoxide poisoning. We have recently commenced commercial sales of the CoSense devices and sampling sets... More >>

Featured Report

Download Documentation 2015 10-K

Stock Quote

SLNO (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%)0.00 (0.00%)
Data as of 06/22/17 3:59 p.m. ET

Recent News


05/11/17Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed merger with Essentialis, Inc. and concurrent financing of $10 million New company name, Soleno Therapeutics, Inc., to reflect new strategic focus on rare disease therapeutics; stock to trade under NASDAQ ticker symbol “SLNO” Scientific advice being obtained from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the development of lead product candidate, Diazoxide Choline Controlled-Release (DCCR) in Prader-Willi syndrome (PWS) Company expect... 
Printer Friendly Version
03/15/17Capnia Reports Fourth Quarter and Full Year 2016 Financial Results
REDWOOD CITY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016. “During the fourth quarter, we embarked on a bold new strategic direction for our Company by signing a definitive agreement to merge with Essentialis, creating a dynamic new organization dedicated to dev... 
Printer Friendly Version
03/08/17Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company
Lead Clinical Asset Entering Phase II/III Development in 2017 for the Treatment of Prader-Willi Syndrome Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones REDWOOD CITY, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced that it has completed its previously-announced merger with privately-held Essentialis, Inc. effective M... 
Printer Friendly Version
02/07/17Capnia to Present at the 19th Annual BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:00 AM ET at the Waldorf Astoria Hotel in New York City. The presentation will be webcast live ... 
Printer Friendly Version

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Capnia Inc posts new information to the site. Just enter your e-mail address and click Submit.

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources